Artwork

内容由Saul Marquez提供。所有播客内容(包括剧集、图形和播客描述)均由 Saul Marquez 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Unlocking New Frontiers in Alzheimer’s Treatment with Christian Howell, CEO of Cognito Therapeutics

19:53
 
分享
 

Manage episode 454777717 series 2893730
内容由Saul Marquez提供。所有播客内容(包括剧集、图形和播客描述)均由 Saul Marquez 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Non-invasive neurostimulation technology can significantly slow cognitive and functional decline in Alzheimer's patients by stimulating brain activity with a new approach.

In this episode, Christian Howell, CEO of Cognito Therapeutics, highlights the limited progress in Alzheimer's disease modification, noting recent monoclonal antibodies targeting amyloid plaque but with concerns about efficacy and cost. He also discusses Cognito's groundbreaking work on Alzheimer's treatments and explains how their innovative device, Spectris, offers a promising non-invasive therapy. Christian explains how Cognito is actively gathering evidence for Spectris' approval and market launch, envisioning its application for various neurodegenerative conditions, broader aging-related cognitive decline, and metabolic health, showcasing the potential of neurostimulation in driving biological brain changes.

Tune in to discover the future of non-invasive neurostimulation and the benefits this new technology could bring to Alzheimer's patients!

Resources:

  • Connect with and follow Christian Howell on LinkedIn.
  • Follow Cognito Therapeutics on LinkedIn and explore their Website.
  • Find the Nature paper about Spectris here.
  continue reading

1861集单集

Artwork
icon分享
 
Manage episode 454777717 series 2893730
内容由Saul Marquez提供。所有播客内容(包括剧集、图形和播客描述)均由 Saul Marquez 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Non-invasive neurostimulation technology can significantly slow cognitive and functional decline in Alzheimer's patients by stimulating brain activity with a new approach.

In this episode, Christian Howell, CEO of Cognito Therapeutics, highlights the limited progress in Alzheimer's disease modification, noting recent monoclonal antibodies targeting amyloid plaque but with concerns about efficacy and cost. He also discusses Cognito's groundbreaking work on Alzheimer's treatments and explains how their innovative device, Spectris, offers a promising non-invasive therapy. Christian explains how Cognito is actively gathering evidence for Spectris' approval and market launch, envisioning its application for various neurodegenerative conditions, broader aging-related cognitive decline, and metabolic health, showcasing the potential of neurostimulation in driving biological brain changes.

Tune in to discover the future of non-invasive neurostimulation and the benefits this new technology could bring to Alzheimer's patients!

Resources:

  • Connect with and follow Christian Howell on LinkedIn.
  • Follow Cognito Therapeutics on LinkedIn and explore their Website.
  • Find the Nature paper about Spectris here.
  continue reading

1861集单集

All episodes

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南